Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA
Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.
Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)
Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.
Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.
Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Establishes expectations for the use of AI in regulatory communications. Emphasizes that MAHs and sponsors are fully responsible for the accuracy of AI-generated content and warns against inaccuracies or 'hallucinations' in inspection responses.
Impacts inspection readiness and CAPA workflows. Organizations using AI for drafting responses must implement quality checks to ensure citations and factual claims are accurate to avoid regulatory non-compliance.
Increased scrutiny of submissions and potential resource strain if AI tools are misused.
Expectations for accuracy and oversight are higher due to AI tool usage.
Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.
The MHRA has released guidance on the use of AI in drafting responses to GxP inspection findings. It underscores that organizations are fully accountable for the accuracy of AI-generated content, warning against inaccuracies that could lead to regulatory non-compliance. The guidance includes higher expectations for submission accuracy due to the use of AI, impacting inspection readiness and corrective action preventive action (CAPA) processes.
What changed: Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.
Why it matters: Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.
Practical implication: Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.
Published from the Firecrawl policy change extraction pipeline.
Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.
Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.
Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.
Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.